LipidLabs, Inc. (LPDL.PK) reported recently that it has agreed to begin distributing the SpectraCell Lipid Analysis test through Wal-Mart’s (NYSE:WMT – News) mini-clinics operated by Intrepid Holdings, Inc. (OTCBB:ITPD – News).
This diagnostic tool is a more precise cholesterol test that allows doctors to identify health risks that traditional screens miss. This advanced analytical technique can help doctors diagnose early warning signs for coronary heart disease, which kills more than 2,600 Americans a day, according to the American Heart Association.
High LDL cholesterol is a major cause of coronary heart disease, according to the National Cholesterol Education Program.
“We want to make this superior life-saving test available to Intrepid’s mini-clinic customers so that they can have the best diagnostic tool available today to determine the risk of heart disease,” stated Thomas Cloud, President of LipidLabs. “As an operator of mini-clinics within Wal-Mart stores, Intrepid allows us to expand access to this test to a new customer base.”
LipidLabs, Inc. is a publicly held technology commercialization company based in Houston, Texas. It developed and commercialized the advanced lipid analysis test that is now manufactured and sold by SpectraCell. It is also currently pursuing the commercialization of high-speed medical communications technology.
Let us hear your thoughts below: